Abstract:Objective To investigate the relationship between the expression of vascular endothelial growth factor (VEGF), its receptors FLT-1, FLK-1/KDR and tumor angiogenesis, clinical staging, lymph node metastasis in non-small cell lung cancer (NSCLC). Methods Immunohistochemical staining and enzyme-linked immunosorbent assay (ELISA) were used to detect the levels of VEGF and its receptors FLT-1,FLK-1/KDR in the tissue and serum of 112 patients with NSCLC, and analysed their clinical significances. Results The expression of VEGF and its receptors FLT-1, FLK/KDR in lung tissue of NSCLC were significantly higher than that in normal alveolar tissue and paracancerous tissue (P<0.05) and they increased significantly in proportion with clinical stages Ⅰ, Ⅱ, Ⅲ-Ⅳ (P<0.05). The positive rates of VEGF and its receptors FLT-1, FLK-1/KDR in lymph node metastasis group were significantly higher than those without lymph node metastasis group (P<0.05). Se- rum VEGF in NSCLC was significantly higher than that in the control group and also increased according to clinical staging (Ⅰ, Ⅱ, Ⅲ-Ⅳ; P<0.05). Serum VEGF was significantly higher in the lymph node metastasis group than that of the absence group (P<0.05) . Conclusions The expression of VEGF and its receptors FLT-1, FLK/KDR in NSCLC increased significantly, and positively correlated with tumor development, progression and lymph node metastasis. Serum VEGF is an important marker of hyperplasia and metastasis in NSCLC.

Expression and clinical study of vascular endothelial growth factor and its receptors FLT-1, FLK-1/KDR in non-small cell lung cancer